KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cme Group (CME) EBITDA: 2009-2025

Historic EBITDA for Cme Group (CME) over the last 17 years, with Sep 2025 value amounting to $999.0 million.

  • Cme Group's EBITDA fell 5.07% to $999.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 billion, marking a year-over-year increase of 7.71%. This contributed to the annual value of $3.9 billion for FY2024, which is 14.43% up from last year.
  • Cme Group's EBITDA amounted to $999.0 million in Q3 2025, which was down 13.63% from $1.2 billion recorded in Q2 2025.
  • Cme Group's EBITDA's 5-year high stood at $1.2 billion during Q2 2025, with a 5-year trough of $631.7 million in Q4 2021.
  • Over the past 3 years, Cme Group's median EBITDA value was $989.7 million (recorded in 2024), while the average stood at $985.5 million.
  • Its EBITDA has fluctuated over the past 5 years, first decreased by 23.36% in 2021, then rose by 29.16% in 2023.
  • Cme Group's EBITDA (Quarterly) stood at $631.7 million in 2021, then rose by 5.79% to $668.3 million in 2022, then grew by 29.16% to $863.2 million in 2023, then climbed by 9.72% to $947.1 million in 2024, then declined by 5.07% to $999.0 million in 2025.
  • Its EBITDA stands at $999.0 million for Q3 2025, versus $1.2 billion for Q2 2025 and $1.1 billion for Q1 2025.